(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Trial Profile

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Betrixaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APEX
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2017 According to a Portola Pharmaceuticals media release, data from this study will be presented at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting.
    • 23 Jun 2017 According to a Portola Pharmaceuticals media release, the U.S. FDA has accepted approved Bevyxxa(betrixaban), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE
    • 07 Mar 2017 According to a Portola Pharmaceuticals media release, new data from this study will be presented in a poster session at the upcoming American College of Cardiology's (ACC) 66th Annual Scientific Session & Expo.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top